Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 ...
Filed by Alvotech (Commission...
Zusammenschluss soll voraussichtlich am bzw. um den 15. Juni 2022 abgeschlossen werden Stammaktien von Alvotech sollen ab 16. Juni 2022 am...
Le regroupement d'entreprises devrait être finalisé (vers) le 15 juin 2022 Les actions ordinaires d'Alvotech devraient être négociées sous le...
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol...
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant false 0001820931 0001820931...
Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp...
false 0001820931 0001820931 2022-05-31 2022-05-31 0001820931 oacb:UnitsEachConsistingOfOneClassAOrdinaryShare0.0001ParValueAndOneFourthOfOneRedee...
Filed by Alvotech (Commission File No. 333-261773) Pursuant to...
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04...
falseQ1Oaktree Acquisition Corp. II0001820931--12-31CAThe Company’s management has broad discretion with respect to the specific application...
Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act...
- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product...
Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지